Skip Navigation

Patrick Forde, M.B.B.Ch.

Patrick Forde, M.B.B.Ch.

Headshot of Patrick Forde
  • Director, Thoracic Oncology Clinical Research Program
  • Associate Professor of Oncology

Languages: English, Irish


Clinical Trials, Lung Cancer, Medical Oncology, Mesothelioma, Non-Small Cell Lung Cancer, Pulmonary Carcinoid Tumors, Small Cell Lung Cancer more

Research Interests

Lung Cancer; Mesothelioma; Clinical Investigation


Skip Viragh Outpatient Cancer Center

201 N. Broadway
Baltimore, MD 21287 map
Phone: 410-955-8893 | Fax: 410-614-9334

Johns Hopkins Bayview Medical Center

300 Mason Lord Drive
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD 21224 map
Phone: 410-550-1711 | Fax: 410-550-1116


Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Co-Director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins and directs the multidisciplinary Thoracic Oncology Clinical Research Program.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer and his work has led to the development of several ongoing phase 3 trials. 

He leads international phase 2 and 3 clinical trials of novel immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America while also serving as principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins. He is focused on providing compassionate, state of the art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners and dedicated staff. more


  • Director, Thoracic Oncology Clinical Research Program
  • Co-Director, Division of Upper Aerodigestive Malignancies
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MBBCh; Royal College of Surgeons in Ireland (2004)


  • Medical Oncology; Beaumont Hospital (2009)
  • Medical Oncology; Mater Misericordiae University Hospital (2008)
  • Internal Medicine; Royal College of Physicians Ireland (2007)


  • Medical Oncology; Cork University Hospital (2010)
  • Oncology; Johns Hopkins University School of Medicine (2014)
  • Medical Oncology; St James's Hospital (2011)

Research & Publications

Selected Publications

View all on PubMed

Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986. PMID:29658848

Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 Nov;27(11):1910-1920. doi: 10.1038/s41591-021-01541-0. Epub 2021 Nov 8. PMID: 34750557

Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018 Aug 1;29(8):1853-1860 PMID: 29982279

Reuss JE, Anagnostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, Wang D, White JR, Yang S, Battafarano R, Broderick S, Bush E, Brock M, Ha J, Jones D, Merghoub T, Taube J, Velculescu VE, Rosner G, Illei P, Pardoll DM, Topalian S, Naidoo J, Levy B, Hellmann M, Brahmer JR, Chaft JE, Forde PM. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020 Sep;8(2):e001282. doi: 10.1136/jitc-2020-001282. PMID:32929052

Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1214-1225. PMID: 30541742

Activities & Honors


  • Fellowship Award, International Association for the Study of Lung Cancer (IASLC), 2013
  • Career Development Award, LUNGevity Lung Cancer Foundation , 2014 - 2017
  • Paul Carbone MD Fellowship Award, 2013
  • Director's Teaching Award in Clinical Science, SKCCC, 2014 - 2015
  • AACR-SU2C Phillip A. Sharp Innovation in Collaboration Award, 2016
  • ESMO Travel Award, 2016
  • Principal Investigator, Translational Team Science Award, US Department of Defense, 2020 - 2024
  • SITC Team Science Award, Society for Immunotherapy of Cancer, 2020


  • American Society of Clinical Oncology
  • International Association for the Study of Lung Cancer
  • Society for Immunotherapy of Cancer
  • American Association for Cancer Research

Videos & Media

Recent News Articles and Media Coverage

Drug reduces size of some lung cancer tumors, relapse rate after surgery. Interview for article reporting on Forde et al. (April 16, 2018) NEJM paper

New studies show hope for turning immune system against lung cancer. Interview for article reporting on Forde et al. USA Today (April 16, 2018) NEJM paper

New Studies Show Immune Treatments Could Be Key in the Fight Against Lung Cancer. Interviewed for article reporting on Forde et al NEJM publication. TIME magazine (April 16, 2018), NEJM paper

Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma, ASCO Post (July 10, 2020)

Immune-boosting drug may help before lung cancer surgery, ABC News (April 12, 2021)

Combination Almost Doubles Survival in Untreated Mesothelioma, MedPage Today (November 11, 2021)

Is this you? Edit Profile
back to top button